Inhibition of BRAF and BRAF+MEK drives a metastatic switch in melanoma
Recent analyses by our group and others showed that the majority of melanoma patients who fail BRAF inhibitor therapy do so at new disease sites. Using phosphoproteomics we showed that BRAF inhibition mediates a switch to an aggressive/metastatic melanoma phenotype that is driven by ligand-independe...
| Main Authors: | , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Taylor & Francis
2015
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4905349/ |